Spero Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Spero Therapeutics, Inc. (SPRO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.22 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.23.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.52, a 12.64% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.74, a 84.39% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.52, a 12.64% decline from fiscal 2023.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.74, a 84.35% decline from fiscal 2022.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $11.12, a 36.89% decline from fiscal 2021.
- Spero Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $17.62, a 61.06% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.22 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $2.23 10-Q · filed 2026-05-13 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.52 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $1.52 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $1.52 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $1.52 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $1.74 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $1.74 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $1.74 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $1.74 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $11.12 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $11.12 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $7.48 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $11.15 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $17.62 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $17.80 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $18.28 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $18.90 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $10.94 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $9.82 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $9.71 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $9.30 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | $8.25 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |